Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential

<p><strong>Background </p></strong>Standard of care treatment of non-muscle invasive bladder cancer (NMIBC) with intravesical Bacillus Calmette Guérin (BCG) is associated with side effects, disease recurrence/progression and supply shortages. We recently showed in a phase I t...

Full description

Bibliographic Details
Main Authors:	Derré, L, Lucca, I, Cesson, V, Bohner, P, Crettenand, F, Rodrigues-Dias, S-C, Dartiguenave, F, Masnada, A, Teixeira-Pereira, C, Benmerzoug, S, Chevalier, MF, Domingos-Pereira, S, Nguyen, S, Polak, L, Schneider, AK, Jichlinski, P, Roth, B, Nardelli-Haefliger, D
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2023

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential

Similar Items